High vitamin D3 diet administered during active colitis negatively affects bone metabolism in an adoptive T cell transfer model

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 305, Issue 1, 2013, Pages

  Larmonier, C B ^a   McFadden, R M T ^a,c   Hill, F M ^a   Schreiner, R ^d   Ramalingam, R ^a   Besselsen, D G ^b   Ghishan, F K ^a   Kiela, P R ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d Medical Care Unit   (Germany)

Author keywords

1,25 dihydroxyvitamin D3; Bone mineral density; Bone turnover; Inflammatory bowel disease

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; COLECALCIFEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; LIGAND; OSTEOCALCIN; OSTEOPROTEGERIN; VITAMIN D RECEPTOR; AMPHIREGULIN; GLYCOPROTEIN; SIGNAL PEPTIDE; VITAMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE; BONE DENSITY; BONE METABOLISM; CD4+ T LYMPHOCYTE; COLITIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; MORPHOLOGY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PLEIOTROPY; PRIORITY JOURNAL; TRABECULAR BONE; VITAMIN BLOOD LEVEL; 1,25-DIHYDROXYVITAMIN D3; ADOPTIVE TRANSFER; ANIMAL; ANIMAL FOOD; BONE TURNOVER; CHRONIC DISEASE; DIET; DRUG EFFECT; ENTERITIS; GENE DELETION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY;

1,25-DIHYDROXYVITAMIN D3; BONE MINERAL DENSITY; BONE TURNOVER; INFLAMMATORY BOWEL DISEASE;

ADOPTIVE TRANSFER; ANIMAL FEED; ANIMALS; BONE AND BONES; BONE DENSITY; CD4-POSITIVE T-LYMPHOCYTES; CHOLECALCIFEROL; CHRONIC DISEASE; COLITIS; DIET; GENE DELETION; GLYCOPROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-10; MICE; MICE, KNOCKOUT; VITAMINS;

EID: 84879589014     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00065.2013     Document Type: Article

References (48)

1. Abreu MT, Kantorovich V, Vasiliauskas EA, Gruntmanis U, Matuk R, Daigle K, Chen S, Zehnder D, Lin YC, Yang H, Hewison M, Adams JS. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut 53: 1129-1136, 2004.
2. Adams JS, Hewison M. Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase. Arch Biochem Biophys 523: 95-102, 2012.
3. Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. Am J Med 122: 599-604, 2009.
4. 3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J Steroid Biochem Mol Biol 103: 381-388, 2007.
5. Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther 18: 1121-1127, 2003.
6. Benchimol EI, Ward LM, Gallagher JC, Rauch F, Barrowman N, Warren J, Beedle S, Mack DR. Effect of calcium and vitamin D supplementation on bone mineral density in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 45: 538-545, 2007.
7. +T cells from IL-10-deficient mice transfer susceptibility to NSAID-induced Rag colitis. Am J Physiol Gastrointest Liver Physiol 287: G320-G325, 2004.
8. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25: 1468-1486, 2010.
9. Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 130: 2648-2652, 2000.
10. Civitelli R, Armamento-Villareal R, Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int 20: 843-851, 2009.
11. Ding S, Schoenmakers I, Jones K, Koulman A, Prentice A, Volmer DA. Quantitative determination of vitamin D metabolites in plasma using UHPLC-MS/MS. Anal Bioanal Chem 398: 779-789, 2010.
12. Dresner-Pollak R, Ackerman Z, Eliakim R, Karban A, Chowers Y, Fidder HH. The BsmI vitamin D receptor gene polymorphism is associated with ulcerative colitis in Jewish Ashkenazi patients. Genet Test 8: 417-420, 2004.
13. El-Hodhod MA, Hamdy AM, Abbas AA, Moftah SG, Ramadan AA. Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease. BMC Gastroenterol 12: 44, 2012.
14. Forster RE, Jurutka PW, Hsieh JC, Haussler CA, Lowmiller CL, Kaneko I, Haussler MR, Kerr Whitfield G. Vitamin D receptor controls expression of the anti-aging klotho gene in mouse and human renal cells. Biochem Biophys Res Commun 414: 557-562, 2011.
15. Froicu M, Cantorna MT. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol 8: 5, 2007.
16. Froicu M, Weaver V, Wynn TA, McDowell MA, Welsh JE, Cantorna MT. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol 17: 2386-2392, 2003.
17. Froicu M, Zhu Y, Cantorna MT. Vitamin D receptor is required to control gastrointestinal immunity in IL-10 knockout mice. Immunology 117: 310-318, 2006.
18. Ghishan F, Kiela P. Metabolic bone disease in inflammatory bowel disease. Practical Gastroenterol XXXVI: 2012.
19. Ghishan FK, Kiela PR. Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol 300: G191-G201, 2011.
20. Hewison M. Vitamin D and immune function: an overview. Proc Nutr Soc 71: 50-61, 2012.
21. Holick MF. Evidence-based D-bate on health benefits of vitamin D revisited. Dermatoendocrinology 4: 183-190, 2012.
22. Holick MF. Vitamin D deficiency. N Engl J Med 357: 266-281, 2007.
23. 3and TPA in a human myelomonocytic cell line, HL60. Bone 32: 621-629, 2003.
24. Kiela PR, Midura AJ, Kuscuoglu N, Jolad SD, Solyom AM, Besselsen DG, Timmermann BN, Ghishan FK. Effects of Boswellia serrata in mouse models of chemically induced colitis. Am J Physiol Gastrointest Liver Physiol 288: G798-G808, 2005.
25. Kim JH, Yamaori S, Tanabe T, Johnson CH, Krausz KW, Kato S, Gonzalez FJ. Implication of intestinal VDR deficiency in inflammatory bowel disease. Biochim Biophys Acta 1830: 2118-2128, 2012.
26. 3 upregulates FGF23 gene expression in bone: the final link in a renalgastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289: G1036-G1042, 2005.
27. Kong J, Zhang Z, Musch MW, Ning G, Sun J, Hart J, Bissonnette M, Li YC. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol 294: G208-G216, 2008.
28. Kuro-o M. Klotho in health and disease. Curr Opin Nephrol Hypertens 21: 362-368, 2012.
29. 3-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1α and receptor activator of NF-κB ligand production in osteoblasts. J Immunol 169: 2374-2380, 2002.
30. Lim WC, Hanauer SB, Li YC. Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2: 308-315, 2005.
31. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17: 1305-1315, 2006.
32. 3enhancement of osteopontin gene expression. Bone 20: 329-334, 1997.
33. 3. J Biol Chem 268: 1456-1461, 1993.
34. Razzaque MS. FGF23, klotho and vitamin D interactions: what have we learned from in vivo mouse genetics studies? Adv Exp Med Biol 728: 84-91, 2012.
35. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 22: 659-661, 2008.
36. 3and phosphorus in vivo. J Biol Chem 280: 2543-2549, 2005.
37. 3and mental well-being: randomised controlled trial. Br J Psychiatry 198: 357-364, 2011.
38. Silva I, Branco JC. Rank/Rankl/opg: literature review. Acta Reumatol Port 36: 209-218, 2011.
39. Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med 239: 131-137, 1996.
40. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 37: 71-76, 1995.
41. Simmons JD, Mullighan C, Welsh KI, Jewell DP. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut 47: 211-214, 2000.
42. Smith H, Anderson F, Raphael H, Maslin P, Crozier S, Cooper C. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women-a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology 46: 1852-1857, 2007.
43. Thearle M, Horlick M, Bilezikian JP, Levy J, Gertner JM, Levine LS, Harbison M, Berdon W, Oberfield SE. Osteoporosis: an unusual presentation of childhood Crohn's disease. J Clin Endocrinol Metab 85: 2122-2126, 2000.
44. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 17: 2393-2403, 2003.
45. 3in mouse osteoblastic MC3T3-E1 cells. J Bone Miner Res 16: 221-230, 2001.
46. Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 7: 609-614, 1995.
47. Wada K, Tanaka H, Maeda K, Inoue T, Noda E, Amano R, Kubo N, Muguruma K, Yamada N, Yashiro M, Sawada T, Nakata B, Ohira M, Hirakawa K. Vitamin D receptor expression is associated with colon cancer in ulcerative colitis. Oncol Rep 22: 1021-1025, 2009.
48. Xue LN, Xu KQ, Zhang W, Wang Q, Wu J, Wang XY. Associations between vitamin D receptor polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: a meta-analysis. Inflamm Bowel Dis 19: 54-60, 2012.